Pharma BD Deal Intelligence
Boehringer Ingelheim International GmbH / Sitryx Therapeutics Ltd.
2026 · Licensing/Option · $500M · Complete
Boehringer Ingelheim acquired an exclusive global license to a preclinical, oral small-molecule program from UK-based Sitryx Therapeutics, targeting a novel immunometabolic mechanism with potential disease-modifying activity across multiple autoimmune and inflammatory indications. Sitryx is eligible for development, regulatory and commercialization milestone payments totalling more than US$500 million plus tiered royalties on future sales; the upfront was not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Feb 26, 2026
- Deal value $500M
- Deal type Licensing/Option
- Therapeutic area Immunology
- Indications Autoimmune and inflammatory diseases (multiple indications)
- Key assets Exclusive license to a preclinical oral small-molecule immunometabolic program from Sitryx Therapeutics
- Mechanism Oral small-molecule immunometabolic modulation
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Boehringer Ingelheim International GmbH deals · Immunology deals